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ABSTRACT 
Human papillomaviruses (HPVs) are responsible for several types of cancer. K14-HPV16 
transgenic mice express the HPV 16 early genes, developing multi-step carcinogenesis 
associated with marked inflammation, as observed in human patients. MicroRNAs 
(MiRNA) constitute a class of non-coding RNAs that regulate gene expression. In particular, 
miR-21 has been associated with carcinogenesis. However, little is known about this microRNA 
in the normal tissue microenvironment and its possible relationship with cancer predisposition. 
We hypothesized that miR-21 expression influences each tissue's susceptibility to HPV-induced 
carcinogenesis. In order to test this hypothesis, we evaluated miR-21 expression in ear and chest 
skin samples from 24-26 weeks old, female K14-HPV16 transgenic and wild-type mice. In wild-
type mice (HPV-/-) miR-21 expression was lower in ear skin compared with chest skin 
(p=0.036). Under the influence of HPV16 oncogenes, transgenic animals (HPV16+/-), developed 
in situ carcinoma in all ear samples and epidermal hyperplasia in chest samples. These results are 
consistent with the hypothesis that microRNA expression in the microenvironment of normal 
tissues may influence HPV-associated carcinogenesis. Furthermore, among transgenic animals, 
miR-21 expression was lower in in situ carcinoma samples compared with hyperplasia 
(p=0,043). This suggests that, despite the well-known role of miR-21 as an oncogene, its anti-
inflamatory and immunomodulatory properties may modulate HPV-induced carcinogenesis in a 
tissue-dependent manner. Further studies are warranted in order to explore the role of 
microRNAs in tissue susceptibility to carcinogenesis.   
Keywords: K14-HPV16, miR-21, microenvironment, in situ carcinoma, hyperplasia 
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INTRODUCTION 
Human papillomavirus (HPV) infection is considered epidemic and may lead to the development of 
cancer. In fact, high-risk human papillomavirus, mainly HPV16 and HPV18, are the agents responsible 
for most cases of cervical cancer and a significant proportion of other types of cancer, such as anogenital 
and head and neck cancers (Major, Szarka, Sziklai, Gergely, & Czegledy, 2005; Walboomers et al., 1999; 
Watson et al., 2008).The prevalence of cervical cancer and high mortality rates, especially in developing 
countries, is alarming and need immediate attention (Ferlay J, 2013).  
K14-HPV16 transgenic mice are a particularly useful model for to study the development of HPV-
associated squamous cell cancers. This model recapitulates multi-step carcinogenesis of uterine cervix 
and skin, starting with hyperplasia that progresses to dysplasia, in situ carcinoma (CIS) and, eventually, 
invasive carcinoma (Coussens, Hanahan, & Arbeit, 1996). In this mouse model, the expression of HPV16 
early region genes (E2-E8) is driven by the cytokeratin 14 (K14) promoter, specifically targeting 
epithelial basal cells (Coussens et al., 1996). Basal cells are mitotically active and thus may develop 
further mutations in response to a proliferative stimulus, and the expression of K14 has been shown to 
persist in well-differentiated squamous carcinomas (Stoler, Kopan, Duvic, & Fuchs, 1988). Although 
several K14-HPV16 transgenic animals develop skin hyperplastic and/or dysplastic lesions in several 
inbred backgrounds, including C57BL/6, BALB/c, and SSIN/SENCAR, only mice backcrossed into the 
FVB/n background progress to malignant squamous cell carcinomas of two pathological grades, well-
differentiated and moderate/poorly-differentiated, each displaying characteristic features of malignant 
behavior (Coussens et al., 1996). Squamous cell carcinomas are observed on 21% of animals aged 8 to 12 
months, on the epidermis of the ear, the chest, and the truncal skin (Arbeit, Munger, Howley, & Hanahan, 
1994; Coussens et al., 1996; Herber, Liem, Pitot, & Lambert, 1996; Song, Pitot, & Lambert, 1999). The 
morphological and molecular similarities between this mouse model and human HPV-induced 
malignancies (Coussens et al., 1996), makes it a useful tool to study epigenetic and genetic factors that 
coordinate malignant conversion and regulate neoplastic progression.  
MicroRNAs (miRNAs) are a class of endogenous small, non-coding RNA molecules of about 21 to 23 
nucleotides that have the capacity to specifically inhibit translation or induce mRNA degradation, 
predominantly through targeting the 3′ untranslated regions (UTRs) of mRNA (Garzon, Calin, & Croce, 
2009). In normal cells, miRNAs control several processes including proliferation, differentiation and 
apoptosis. Because of their wide variety of targets, miRNAs have been found to affect numerous 
4 
developmental processes within cells including hematopoietic lineage differentiation, immunity, 
inflammation, and tumorigenesis (Chen, 2005; Stahlhut Espinosa & Slack, 2006).  
MicroRNA-21 (miR-21) has been implicated in various aspects of carcinogenesis. In some cancers, miR-
21 is overexpressed and thus promotes cell proliferation and reduces apoptosis (Chan, Krichevsky, & 
Kosik, 2005; Iyevleva et al., 2012; Kulda et al., 2010). Previous studies suggest that, as an oncogenic 
miRNA, miR-21 has a role not only in tumor growth but also in invasion and metastasis, by targeting 
multiple tumor/metastasis suppressor genes (Zhu et al., 2008). Recently, scientific community has started 
to debate whether miRNAs can be used as possible markers for the occurrence and development of the 
HPV-associated cancers (Ribeiro & Sousa, 2014). However, in this cancers, the interplay between miR-
21 and HPV genes remain elusive and poorly understood. The tissue microenvironment is also 
responsible for miRNAs regulation, and may, in this way, play a role in neoplastic transformation 
(Whiteside, 2008).  
In the present study, we aimed to analyzed miR-21 expression in skin samples with or without the 
presence of integrated HPV DNA and with different HPV-associated lesions. For this purpose, we have 
used K14-HPV16 transgenic mice, (Arbeit et al., 1994), to analyze miR-21 expression in ear and chest 
skin samples, evaluating its association with tissue microenvironment and predisposition to HPV-induced 
carcinogenesis. 
5 
MATERIAL AND METHODS 
K14-HPV16 transgenic mice 
K14-HPV16 mice generation has been previously reported (Arbeit et al., 1994). K14-HPV16 mice on a 
FVB/n background were generously donated by Drs. Jeffrey Arbeit and Douglas Hanahan, from the 
University of California, through the USA National Cancer Institute Mouse Repository. After one week 
quarantine, the animals were maintained and bred in accordance with Portuguese (Portaria 1005/92 dated 
October the 23
rd
) and European (EU Directive 2010/63/EU) legislation, under controlled conditions of 
temperature (23±2 ºC), light-dark cycle (12 h light/12 h dark) and relative humidity (50±10%), using 
hardwood bedding. A standard diet (4RF21 GLP, Mucedola, Italy) and water were provided ad libitum, 
and health checks were performed daily. A total of 15 female mice from consecutive litters were selected 
for the study. 
Genotyping of HPV16-E6 and E2 
The mice were genotyped at weaning, using tail tip samples. To tissue lysis added 300μL of MagnaPure 
DNA Tissue Lysis Buffer (Roche®, Indianapolis, USA) and 20 μL of Proteinase K. After, incubated 
overnight (16h) at 65 °C. Nucleic acids were extracted using the High Pure Viral Nucleic Acid kit 
(Roche®, Indianapolis, USA) following the manufacturer's instructions. DNA purity was assessed by the 
ratio of the absorbance values at 260/280 nm, using the NanoDrop® spectrophotometer v3.7 (Thermo 
Scientific, Wilmington DE, USA). The presence of amplifiable genomic DNA was tested by polymerase 
chain reaction (PCR) amplification of mouse β-globin using specific primers (Table 1) (Konkel, 
Tilghman, & Leder, 1978). The PCR reaction was performed in a 50 μl solution with 1x Taq buffer, 2.0 
mM MgCL2, 0.2 mM DNTP’S, 0.50 μM of each primer, 1 U de Taq DNA Polimerase and 0.2 µg of 
genomic DNA. The amplification conditions were as following: denaturation of DNA template at 94 ºC 
for 3 min, followed by 35 cycles at 94 ºC for 30 s 60 ºC for 45 s, 72 ºC for 90 s, and a final extension step 
at 72 ºC for 10 min. The amplified fragment of 494 base pairs (bp) was analyzed by electrophoresis in 1.5 
% (w/v) agarose gels stained with ethidium bromide and visualized under UV light. 
The integration of  HPV was assessed by amplification of HPV16-E6 and HPV16-E2 genes with specific 
primers (Table 1), which amplify a region of 130 bp and 184 bp, respectively, (adapted from a protocol 
described by Cañadas et al. and Ribeiro et al (Canadas et al., 2010; Ribeiro et al., 2014)). The PCR 
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amplification reaction with HPV16-E6 and HPV16-E2 primers was carried in a 50 µl reaction mixture 
with 1x PCR Buffer, 2.5 mM MgCl2, 0.2 mM DNTP’S, 0.30 µM of each primer, 1 U of Taq DNA 
polymerase and 0.2 µg of genomic DNA. Thermal cycling was performed as follows: initial denaturation 
of DNA template at 94 ºC for 2 min, followed by 35 cycles at 94 ºC for 1 min, 60 ºC for 1 min, and 72 ºC 
for 1 min and a final extension step at 72 ºC for 5 min. The amplified fragment was analyzed by 
electrophoresis in 1.5 % (w/v) agarose gels stained with ethidium bromide and visualized under UV light.  
The resulting genotypes were compared with the respective phenotypes. 
Table 1 – Primer sequences 
Target/Name Amplicon Sequence 
Mouse β-globin 
MBG_fwd 494 bp 5’-CCAATCTGCTCACACAGGATAGAGAGGGCAGG-3’ 
MBG_rev 5’-CCTTGAGGCTGTCCAAGTGATTCAGGCCATCG-3’ 
HPV16-E6 
HPV16_E6fwd 130 bp 5’-AAAGCCACTGTGTCCTGA-3’ 
HPV16_E6rev 5’-CTGGGTTTCTCTACGTGTTTC-3’ 
HPV16-E2 
HPV16_E2fwd 184 bp 5’-TTTAGCAGCAACGAAGTATCC-3’ 
HPV16_E2rev 5’-AGTCTCTGTGCAACA ACTTAG-3’ 
Sample collection 
Eight hemizygous (+/-) and seven wild-type (-/-) females were sacrificed at 24 to 28 weeks of age by 
using sodium pentobarbital followed by intracardiac punction and exsanguination, as indicated by the 
Federation for Laboratory Animal Science Associations (FELASA). Ear and chest skin samples from 
each animal (13 samples from transgenic and 14 samples from wild-type animals) were collected into 
TriPure reagent (Roche® Applied Science), macerated, and kept at -80 ºC until processing. Matched 
samples were collected into 10% neutral buffered formalin for routine histological processing. 
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Histological sections (2 µm-thick) were stained with haematoxylin and eosin (H&E) for examination 
on light microscopy. Samples were classified as normal skin, epidermal hyperplasia and epidermal CIS 
by two independent researchers (CL and RGC), as previously described (Arbeit et al., 1994). In 
order to analyse tumour-associated inflammatory cell infiltration, leukocytes were counted in the 
neighbouring dermis. Total leukocytes and each leukocytic population were assessed in 3 adjacent 
high power fields and expressed as the mean ± standard deviation.  
Analysis of miRNA expression 
Extraction of total RNA from samples preserved in TriPure reagent was performed using the High Pure 
Viral Nucleic Acid kit (Roche®, Indianapolis, USA), according to manufacturer’s instructions. 
RNA quality was assessed using NanoDrop® spectrophotometer v3.7 (Thermo Scientific, 
Wilmington DE, USA). 
Hsa-miR-21_000397 and snoRNA-202_001232 were analyzed using two-step real-time PCR protocols 
with TaqMan® MicroRNA Assays (Applied Biosystems, Foster CA, USA). The conversion of miRNA to 
cDNA was performed using TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems®, 
Foster CA, USA) in a 15 µL of total volume reaction mix with: 7 μL of a master mix containing 1x RT 
buffer, 1.0 mM of total dNTPs, 50U MultiScribe Reverse Transcriptase Enzyme and 0.25U of RNase 
inhibitor; 3 μL of RT primers (Applied Biosystems, Foster CA, USA); and 5μL of RNA sample. The 
amplification conditions were as follows: 30 min at 15 ºC, 52 min at 42 ºC and finally 10 min at 85 ºC. 
All reverse transcriptase reactions included two non-template controls using double distilled water to 
replace template RNA. 
qPCRs were performed on a StepOne Real-time PCR System (Applied Biosystems, Foster CA, USA) 
with a 20 μl final volume: 1× TaqMan® Universal PCR Master Mix II (Applied Biosystems, Foster City, 
California USA); 1x MicroRNA Assay (Applied Biosystems, Foster City, California USA); and 2 μL 
cDNA from RT snoRNA-202 was used as endogenous control. Thermal cycling conditions were: 10 min 
at 95 °C followed by 45 cycles of 15 s at 95 °C and 1 min at 60 °C. All reactions included two-template 
controls using double distilled water to replace template cDNA. 
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Statistical Analysis 
Data analysis was performed using the software IBM®SPSS ®Statistics for Windows (Version 20.0). 
The T-Student test was used in order to evaluate any statistical differences in the normalized expression 
of the miR-21. In order to analyze the normalized relative expression (-ΔCt) of the different groups, we 
considered the results corresponding to a 99% representation of the population ( X ± 2SD). 
RESULTS 
Analysis of genotyping vs phenotyping and tumour-associated inflammatory cell infiltration 
In 8 out of 15 mice we observed the presence of HPV16 integration (Figure 1). All animals with 
integrated HPV16 DNA presented a phenotype characteristic of HPV-associated lesions, as 
persistent epidermal squamous hyperplasia in various degrees and hyperkeratosis, as previously described 
(Arbeit et al., 1994) (Figure 2). Wild-type mice did not develop any skin lesions. Also, we observed in 
histologic evaluation that in all cases with integrated HPV16 DNA, the chest skin presented epidermal 
hyperplasia while the ear skin showed CIS. Wild-type mice presented, as expected, normal skin histology 
(Figure 3).  
HPV-transgenic mice showed increased numbers of tumour-associated leukocytes compared with 
wild-type animals (Table 2). Ear skin (presenting with CIS) showed increased inflammatory cell 
infiltration Mainly neutrophils) when compared with chest skin (hyperplasia). From the analysis 
of tumour-associated inflammatory cell infiltration, we observed that there is an increase in the 
number of leukocytes in the inflammatory infiltrate of CIS comparatively with tissue that showed 
hyperplasia. The normal histology of chest and ear tissue presented fewer leukocytes compared to tissue 
with hyperplasia and CIS. (Table 2)  
Fig. 1 Genotyping of HPV16-E6 and E2 in mice.  The presence of integrated HPV was assessed by 
amplification of HPV-E2 (b) and HPV-E6 (c) genes by polymerase chain 
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reaction methodology (PCR) in-house. Samples 1 and 3 are HPV+; sample 2 is HPV-. Mouse-β-globin 
gene was used as endogenous control (a). M: molecular weight size marker: (a)100 bp, (b,c)50 bp; C-: 
negative control  
Fig. 2 Wild-type (HPV16 -/-) and K14-HPV16 transgenic (HPV16 +/-) mice. Transgenic mice show a 
hunched position, partial thoracic and cephalic alopecia, together with extensive hyperkeratosis 
and auricular erythema.   
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a) 
b) 
c) 
Fig. 3 a) Wild-type (-/-) female FVB/n mouse. Chest skin showing normal histology. H&E, 200x 
bar=50µm b) K14-HPV16 transgenic (+/-) female FVB/n mouse. Chest skin showing epidermal 
hyperplasia and orthokeratotic hyperkeratosis. Note increased number of epidermal strata with conserved 
orderly squamous differentiation. c) K14-HPV16 transgenic (+/-) female FVB/n mouse. Ear skin showing 
in situ carcinoma. Note loss of epidermal stratification and progressive differentiation, presence of 
suprabasal mitotic figures and anisocytosis and abrupt parakeratotic keratinization with hyperkeratosis. 
The underlying stroma exhibits intense mixed inflammatory cell infiltration and neovascularization.  
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Table 2. Tumour-associated inflammatory cell infiltration in HPV16 -/- and HPV16 +/- mice. 
Total leukocytes and each leukocytic population were assessed in 3 adjacent high power fields and 
expressed as the mean ± standard deviation. 
MiRNA-21 expression profile in skin tissues from wild-type mice 
We quantified the miR-21 expression in normal skin tissues (wild-type mice) and we verified that the ear 
tissues presented lower expression levels compared with chest tissues (p=0.036) (Figure 4a). 
MiRNA-21 expression profile in skin tissues of transgenic mice 
To evaluate the miR-21 expression in tissues from transgenic mice, we analyzed ear and chest skin 
samples. Similarly to that detected in wild-type mice, we observed lower expression levels of miR-21 in 
ear tissues (histologically presenting with CIS) when compared with chest tissue (histologically 
presenting with epidermal hyperplasia) (p=0.043) (Figure 4b). 
Genotype Tissue Histology Macrophages Neutrophils Lymphocytes Mast cells Plasma cells Total 
leukocytes 
HPV16 -/- 
chest normal 0,5 ± 0,4 0,1 ± 0,1 0,1 ± 0,3 1,5 ± 0,5 0,2 ± 0,3 2,3 ± 0,7 
ear normal 0,6 ± 0,4 0,1 ± 0,1 1,1 ± 0,3 1,9 ± 0,5 0 ± 0,2 3,4 ± 0,8 
HPV16 +/- 
chest hyperplasia 6,6 ± 3,5 3,6 ± 2,7 4,3 ± 3,7 5,5 ± 2,3 2,2 ± 1,2 22,1 ± 2,9 
ear CIS 44,8 ± 10,6 138,7 ± 122,5 11,8 ± 10,51 22,5 ± 16,9 0,3 ± 0,5 218,2 ± 113,0 
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Fig. 4 Normalized relative expression of miR-21 in ear and chest normal tissue (a). Normalized 
expression of miR-21 in different lesions of K14-HPV16 transgenic mice (CIS and hyperplasia) (b). 
MiRNA-21 expression profile in tissue of transgenic versus wild-type mice 
To investigate a possible direct influence of HPV16 on the miR-21 expression profile, we compared the 
relative expression between tissues (ear and chest) of transgenic mice and wild-type mice. Our data 
showed no statistical significant difference in miR-21 expression levels between both groups (p=0.615). 
Identically, no differences were found when we compared miR-21 expression in ear (p=0.486) and chest 
(p=0.731) samples, separately, between transgenic and wild type mice (Figure 5). 
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Fig. 5 Normalized relative expression of miR-21 in transgenic mice (HPV+) and wild-type mice (HPV-), 
in ear (a) and chest tissue (b). 
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DISCUSSION 
The elucidation of the importance of miRNAs in tumor biology is a rapidly growing field in oncology 
research, because it holds promise for disease prognosis and targets for the development of novel cancer 
therapeutics (Garzon, Marcucci, & Croce, 2010; Nelson & Weiss, 2008).  
MiR-21 is a highly overexpressed miRNA in several cancers. Its overexpression has been observed in 
head and neck, cervical, ovarian, lung, liver, stomach and pancreatic cancers (Guo et al., 2009; Hui et al., 
2010; Jiang et al., 2008; Lee et al., 2007; T. Yao & Lin, 2012; Zhang et al., 2010). Previous studies 
indicate that HPV infection is the main factor driving the transition from normal cervical epithelium to 
cervical preneoplastic lesions, intraepithelial neoplasia and, successively, to invasive cervical cancer 
(Bosch & de Sanjose, 2007; zur Hausen, 2002). The influence of others factors, such as the host 
microenvironment, remains poorly understood. In particular, no conclusive evidence exists concerning 
the relation between HPV and miR-21 expression in cervical cancer, the most important HPV-associated 
tumor.  
K14-HPV16 transgenic mice are a useful experimental model for studying HPV-induced carcinogenesis. 
The FVB/n mouse strain is particularly prone to HPV-driven carcinogenesis, as other mouse strains (e.g. 
Balb/c, C57Bl/6, SSIN/SENCAR) bearing an identical transgene, failed to develop invasive carcinomas 
(Coussens et al., 1996). This observation highlights the key role of host factors in the development of 
HPV-associated tumors. 
Our results indicate that, among wild-type mice (HPV-/-), the expression of miR-21 is lower in ear skin 
tissue compared with chest skin (p=0.036). Furthermore, in matched 24-26 weeks-old transgenic animals 
(HPV16+/-), we found that CIS had developed in all ear skin samples, whereas chest skin samples only 
showed epidermal hyperplasia. Consistently, in these samples, miR-21 expression was lower in CIS (ear 
skin) samples when compared to hyperplasia (chest skin) (p=0,043). We conclude that the expression of 
miR-21 in normal tissues could be an important factor in the local microenvironment favoring the 
development of HPV-associated tumors. 
Several studies have expanded the concept that inflammation is a critical component of tumor 
progression, including HPV-associated tumors (Boccardo, Lepique, & Villa, 2010). Many cancers arise 
from sites of infection, chronic irritation and inflammation (Coussens & Werb, 2002). Among other 
phenomena, inflammation promotes stromal remodeling and inflammatory cell infiltration (Neuchrist et 
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al., 1990; Ortegel, Staren, Faber, Warren, & Braun, 2000), including monocytes/macrophages, B and T 
lymphocytes, NK cells, and neutrophils. Our results confirm that tumour progression is accompanied by 
increased inflammatory cell infiltration, especially macrophages and neutrophils. In our study we 
found that there is an increased of inflammation with tumor progression by infiltration of leucocytes 
especially macrophages and neutrophils. In K14-HPV16 transgenic mice, a deficiency in CD4+ T cells has 
been previously shown to modulate inflammation, delaying neoplastic progression and lowering 
tumor incidence (Daniel et al., 2003).  
Considerable evidence indicates that miR-21 has anti-inflammatory properties. Previous studies reported 
that miR-21 silences the pro-inflammatory interleukin 12 (IL-12) (Lu et al., 2011). IL-12 is a major 
cytokine that regulates Th1 versus Th2 decisions, primarily by inducing T cells to produce the Th1 
cytokine IFN-γ (Gately et al., 1998), leading to enhanced inflammation and tumor progression. Other 
studies demonstrated that elevated levels of several pro-inflammatory, type-1 interleukins, like Il-12, 
were indicators of cervical HPV persistence, underscoring the potential negative biological effects of 
prolonged inflammation (Scott et al., 2013). Our results are in accordance with these reports, suggesting that high 
levels of miR-21 may decrease inflammation, possibly by interacting with Il-12 and, thus, reduce
countering malignant transformation. 
Furthermore, IL-1β is a target of miR-21 and this cytokine has an important role in inflammation 
(Apte & Voronov, 2008). This is a pro-inflammatory cytokine associated with stimulation of the tumor 
microenvironment in favor of increased cell proliferation and tissue angiogenesis (Voronov et al., 2003). 
These results are consistent with our findings, suggesting that low levels of miR-21 may be 
associated with high levels of Il-1β, thus promoting the increase of inflammation and, consequently, 
the carcinogenic process. 
Programmed cell death 4 (PDCD4), a tumor suppressor gene, is an important functional target of the 
miR-21 in several cancers, including in cervical cancers (Q. Yao, Xu, Zhang, Zhou, & Qu, 2009). This 
target is a pro-inflammatory protein that promotes activation of the transcription factor NF-kB and 
suppresses the anti-inflammatory interleukin 10 (IL-10).  Some studies observed that miR-21 directly 
blocked NF-kB activity and promoted IL-10 production (Sheedy et al., 2010). NF-kB can act as an 
oncogene through its ability to stimulate inflammation, cell proliferation and survival. NF-kB is 
constitutively activated in several human cancers (Li, Withoff, & Verma, 2005), including cervical cancer 
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(Branca et al., 2006; Nair, Venkatraman, Maliekal, Nair, & Karunagaran, 2003) and has been proposed to 
be an important link between chronic inflammation and cancer (Karin, 2009). In our study, low levels of 
miR-21 may promote NF-kB activation, through of PDCD4 expression, and, thus, increase the 
predisposition to cancer development. 
Conclusion 
Previous data correlating miR-21 downregulation with increased inflammation, may explain our findings 
suggesting that tissues with lower miR-21 expression are more prone to cancer progression. These 
findings are important in the quest to gauge the utility of miR-21 expression in evaluation of tissues with 
higher predisposition to cancer development. 
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